Table 4.

Ten most represented Investigational Medicine Products (IMP) on ongoing clinical trials for the treatment of COVID-19 and potential impact for cancer patients.

IMP	NCT identifier	Documented/hypothetical mechanism of action	Potential impact for cancer patients
Allogeneic Mesenchymal Cells	NCT04366271, NCT04361942, NCT04339660, NCT04252118 NCT04313322, NCT04348461, NCT04336254, NCT04348435 NCT04315987, NCT04273646, NCT04366830, NCT04346368 NCT04288102, NCT04293692, NCT04352803, NCT04366063 NCT04366323, NCT04349631, NCT04377334, NCT04345601 NCT04355728, NCT04382547, NCT04333368, NCT04302519 NCT04371601, NCT04341610, NCT04269525, NCT04276987	Immunosuppressive and tissue repair properties	No potential impact [96]
Angiotensin-converting-enzyme inhibitors Angiotensin receptor blockers	NCT04329195, NCT04335136, NCT04375046, NCT04287686 NCT04345406, NCT04353596, NCT04364893, NCT04337008 NCT04351581, NCT04330300, NCT04338009, NCT04332666 NCT04375124, NCT04335123, NCT04312009, NCT04311177 NCT04340557, NCT04366050, NCT04355936, NCT04360551, NCT04335786	Anti-hypertensive agents inhibiting virus entry into the host cell (mediated by ACE2 receptor)	No potential impact
Bacille Calmette-Guérin Vaccine	NCT04327206, NCT04328441, NCT04379336, NCT04362124 NCT04350931, NCT04369794, NCT04373291, NCT04348370, NCT04384549	Live vaccine	Risk of live attenuated vaccine
Chloroquine Hydroxychloroquine	NCT04362332, NCT04359537, NCT04328272, NCT04351919 NCT04346329, NCT04329611, NCT04345653, NCT04351516 NCT04370262, NCT04352933, NCT04347889, NCT04350450 NCT04364815, NCT04369742, NCT04363866, NCT04382625 NCT04340544, NCT04329923, NCT04351620, NCT04333225 NCT04345692, NCT04323631, NCT04331834, NCT04371926 NCT04385264, NCT04315896, NCT04354870 NCT04342221, NCT04353271, NCT04372017, NCT04358068 NCT04330495, NCT04318444, NCT04330144, NCT04318015 NCT04381988, NCT04261517, NCT04379492, NCT04341441 NCT04370015, NCT04354441, NCT04328961, NCT04363827 NCT04334967, NCT04363450, NCT04332991, NCT04361461 NCT04384380, NCT04334148, NCT04342169, NCT04342156 NCT04321278, NCT04371523, NCT04333654, NCT04374942 NCT04325893, NCT04353037, NCT04316377, NCT04308668 NCT04303507, NCT04336748, NCT04349371, NCT04333732 NCT04333628, NCT04328493, NCT04344951, NCT04331600 NCT04353336, NCT04360759, NCT04346667, NCT04342650 NCT04323527, NCT04328467, NCT04304053, NCT04351191 NCT04349228, NCT04352946, NCT04349228	Increase of lysosomes pH Membrane fusion and endocytosis inhibition	Elimination half-life of 10–30 days [97] CYP2D6 inhibitor [98] Cardiac toxicity (QT prolongation) Ocular toxicity (e.g. MEK inhibitors)
Colchicine	NCT04350320, NCT04375202, NCT04355143, NCT04367168 NCT04360980, NCT04326790, NCT04328480, NCT04322565 NCT04363437, NCT04322682	Anti-inflammatory and antimitotic	CYP3A4 substrate [99]
Convalescent Plasma Therapy	NCT04346446, NCT04345679, NCT04383548, NCT04344535 NCT04355897, NCT04338360, NCT04374487, NCT04343261 NCT04345991, NCT04354831, NCT04356534, NCT04372979 NCT04321421, NCT04345523, NCT04343755, NCT04347681 NCT04376788, NCT04385043, NCT04348877, NCT04384497 NCT04372368, NCT04344015, NCT04333355, NCT04348656 NCT04365439, NCT04361253, NCT04380935, NCT04353206 NCT04363034, NCT04342182, NCT04358211, NCT04352751 NCT04384588, NCT04374149, NCT04374370, NCT04385199 NCT04381858, NCT04355767, NCT04374526, NCT04373460 NCT04375098, NCT04377568, NCT04383535, NCT04366245 NCT04360486, NCT04364737, NCT04356482, NCT04340050 NCT04374565, NCT04358003, NCT04323800, NCT04332380 NCT04357106, NCT04332835, NCT04359810, NCT04327349 NCT04385186, NCT04376034, NCT04358783, NCT04377672 NCT04374539, NCT04325672, NCT04333251, NCT04380532 NCT04346589, NCT04264858	Passive immunity	No data available
Nitric Oxyde Gas	NCT04290858, NCT03331445, NCT04338828, NCT04383002 NCT04305457, NCT04312243, NCT04290871, NCT04337918 NCT04306393, NCT04358588	Vasodilatation	No potential impact
Ruxolitinib	NCT04348071, NCT04355793, NCT04362137, NCT04359290 NCT04354714, NCT04377620, NCT04338958, NCT04337359 NCT04334044, NCT04331665	JAK2 inhibitor	CYP3A4 and CYP2C9 substrate (no clinically relevant) [100]
Tinzaparin Enoxaparin	NCT04344756, NCT04366960, NCT04345848, NCT04362085 NCT04359277, NCT04377997, NCT04373707, NCT04360824 NCT04367831, NCT04354155	Anticoagulant	No potential impact
Tocilizumab	NCT04345445, NCT04317092, NCT04377750 NCT04331795, NCT04377659, NCT04361032, NCT04346355 NCT04320615, NCT04372186, NCT04363736, NCT04335071 NCT04377503, NCT04363853, NCT04356937, NCT04370834 NCT04315480, NCT04361552, NCT04331808	Anti-IL-6	Induction of cytochromes P450 and increase elimination of associated substrates [101]

IL: Interleukin; IMP: Investigational Medicine Product; SPC: Summary of Product Characteristics.

Note: the trials summarized were these referenced on ClinicalTrial.gov until May, 15th 2020. An exhaustive table of ongoing trials evaluating medical strategy is displayed in Appendix. The Cochrane France organization provides a website (https://covid-nma.com/) dedicated to map current researches on the prevention and treatment of COVID-19 (weekly update) and to review study results as soon as they are available (daily updated).